H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025Psyence Group2025-08-28T19:09:59+02:00August 28, 2025|Read More
Psyence Biomed Study Featured on TV Channel 9 News AustraliaPsyence Group2025-08-12T14:14:27+02:00August 12, 2025|Read More
Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionPsyence Group2025-07-31T14:51:56+02:00July 31, 2025|Read More
Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing RequirementsPsyence Group2025-06-17T09:38:38+02:00June 17, 2025|Read More
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical TrialPsyence Group2025-05-27T14:44:03+02:00May 27, 2025|Read More
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyPsyence Group2025-04-21T08:16:12+02:00April 21, 2025|Read More
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply AgreementPsyence Group2025-04-15T14:50:08+02:00April 15, 2025|Read More